Participated · Seed · May 2026

LawX develops an AI-driven platform that automates operational processes for law firms and notaries, including data capture, workflow management, document handling, contact and calendar management, and billing. The platform combines case management, workflow automation, document processing, communication management and billing within a single system. LawX positions itself to address fragmented legacy systems and labour shortages that leave many operational tasks manual across the legal sector. The company plans to expand its product offering into the broader law firm market and aims to become a leading operating system for legal work across Europe. Following its €7.5 million seed raise, LawX intends to use the funding to continue product development, expand the platform, and scale sales and customer support functions.

Participated · Seed · May 2025

Penzilla develops a SaaS platform that simplifies administration of company pension schemes by uniting HR, payroll and pension providers on a single system. The product aims to make occupational pensions simpler, more accessible and more efficient for employers and employees, reducing administrative burdens and legal risks. Its platform integrates with payroll and HR systems (e.g., Personio, HiBob, Rexx, DATEV) and has sales partnerships with major pension providers including Allianz, Swiss Life, Canada Life, WWK and Signal Iduna. Well-known customers such as Lacoste, Notebooksbilliger.de and ProSiebenSat.1 use Penzilla, and the company manages schemes for thousands of employees and pensioners. Penzilla plans to use its recent funding to invest in market development and to strengthen its position as a leading software platform for bAV management. Founded in 2022 and based in Munich, the startup emphasizes a software-first approach to address the complex needs of large SMEs and international corporations.

Participated · Seed · Feb 2025

Founded in 2021, Cologne-based Planted has built an AI-driven ESG platform that guides companies through the full sustainability workflow, from double-materiality assessments and carbon accounting to decarbonisation initiatives and final CSRD reports. Its technology extracts data from existing documents, recommends emission-reduction measures, and highlights risks and opportunities, cutting users’ reporting time by up to 75 %. Beyond compliance, the software connects customers to local environmental projects such as mixed-forest plantings and typically helps them achieve emission reductions of more than 50 %. The company already supports more than 350 corporate customers in Germany. Planted positions its product as a way to turn CSRD obligations into strategic advantages, marrying ecological responsibility with measurable economic benefits. The recent €5 million seed infusion strengthens its balance sheet to accelerate product development and market expansion. No revenue figures were disclosed in the article.

Led · Seed · Dec 2024

eyva.ai provides an AI-driven platform to help product teams uncover portfolio gaps, identify opportunities for new launches, optimize existing products, and phase out underperformers in the beauty and wellness sector. The company positions itself against fragmented, single-point solutions that it says cost companies over €100,000 and fail to deliver decision-making value. eyva.ai cites industry challenges such as nearly 60% of new product launches failing and employees spending an average of 10 hours per week on research and concept development. The startup plans to expand beyond Product Management to integrate Marketing and R&D functions. It is also exploring internal data integrations to improve risk identification. Financially, eyva.ai recently completed a €2.7M seed round to support these product and integration efforts.

Participated · Equity · Oct 2023

Mybacs is described in the article as operating in biotech, health services and pharmaceutical sectors. On 22 October 2023 the company completed a €5.6 million equity financing, reported at roughly $5.99 million. The round listed participation from NaturalX Health Ventures, Wenvest Capital, SevenVentures, Global Founders Capital (GFC), Joyance Partners and G‑Fund. Coverage of the transaction in the cited text focuses on the financing amount and investor roster rather than product detail or operating metrics. The financing represents a capital injection from a mix of investment groups named in the announcement. Mybacs develops highly-dosed synbiotic dietary supplements composed of selected bacterial cultures, prebiotics, vitamins and minerals, tailored to specific customer needs and applications. The company launched Travelbacs in 2018 and later expanded its portfolio with Dailybacs, a subscription synbiotic for daily use for women, men and children. After a successful first financing in August 2019, Mybacs has completed a Seed II round to continue its growth. Participants in the new round include existing investor Global Founders Capital, returning business angels, and San Francisco–based Joyance Partners as the first international investor. The funds will be used to grow the team, develop personalized products and build a dedicated tech platform. Mybacs plans to hire specialists in technology and data and to develop a platform for symptomatic and intelligent data analysis to drive further product personalization and development. mybacs is a B2C biotech startup that develops personalized synbiotic products targeting the human gut microbiome for intestinal health. In February 2019 the company launched the world’s first regionally adapted synbiotics for prevention of travelers' diarrhea, offering 5-day capsule treatments tailored to different geographic pathogenic profiles. Products are available for Africa & the Middle East, Asia, Europe & North America, and Latin America. In the first six months after launch the startup grew greatly and currently sells through its own online shop (mybacs.co), Amazon, BRACK.CH, numerous German and Swiss pharmacies, and plans to sell through airlines. The newly closed seed financing will be used to launch another product line, expand personnel, and increase sales and marketing activities. Long-term plans include expanding the gastrointestinal health product portfolio, introducing a daily-use subscription product line in October, and offering an app to track users' health progress.